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Abstract
Background: The role of  the immune system in insulin resistance associated with type 2 diabetes has been suggested.
Objectives: We assessed the profile of  Th1/Th2 cytokines along with the frequencies of  immune cells in insulin-treated type 2 
diabetic patients (T2DP).
Methods: 45  T2D patients and 43 age-matched healthy subjects were selected. Serum concentrations of  T-helper type 1 (Th1) 
and Th2 cytokines and the frequencies of  innate and adaptive immunity cells were assessed.
Results: T2DP were hyperglycemic and showed high level of  insulin, normal levels of  triglycerides and total-cholesterol and 
without any change in HDL-cholesterol.Compared to healthy subjects, T2DP exhibited significant decreased frequencies of  
neutrophils, without any change in monocytes, eosinophils and natural killer cells. The percentages of  total lymphocytes (CD3+) 
and CD8+-T-cells decreased whereas those of  regulatory T-cells increased without any change in CD4+ T-cells in T2DP. In-
terestingly, the frequencies of  effector CD4+-T and B-cells increased in T2DP. Serum concentrations of  IL-2, IFN-γ and IL-4 
decreased while IL-10 significantly enhanced in T2DP, suggesting a differentiation of  CD4+T helper cells towards IL-10-pro-
ducing-Teff-cells in these patients.
Conclusion: Insulin-treated type 2 diabetes is associated with anti-inflammatory profile consistent with differentiation of  
CD4+-Th-cells towards IL-10-producing-Teff-cells, concomitant with increased frequencies of  Treg and B-cells, and this may 
probably offer prevention against certain infections or autoimmune/inflammatory diseases.
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Introduction
Type 2 diabetes mellitus is one of  the most important ep-
idemic diseases in the world. It accounts for 90% of  cases 
of  diabetes1-3. Type 2 diabetes is a group of  metabolic 
disorders characterized by chronic hyperglycemia associ-
ated with abnormalities of  the metabolism of  carbohy-
drates, fats and proteins resulting in insulin resistance1-3. 
It is mainly the result of  sedentary lifestyle, excess body 
weight and physical inactivity3. 
Besides, evidence is now arising and suggesting the 
pathological role of  immune system in the chronic in-
flammation and insulin resistance observed in type 2 
diabetes. Indeed,type 2 diabetes results from generalized 
activation of  innate immune system, in which there is a 
chronic cytokine-mediated inflammation4-6. These cyto-
kines act on liver, adipose tissue, brain, and pancreatic 
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β-cells leading to a disrupted lipid metabolism which is 
the main risk factor for atherosclerosis, obesity and insu-
lin resistance associated with type 2 diabetes7,8. We have 
previously demonstrated, in human and animal studies, 
the implication of  T-cell differentiation through Th1/
Th2 cytokines in the modulation of  gestational diabetes 
and macrosomia9-13. Nowadays, it is well known that naïve 
Th0 cell can differentiate into specific Th subsets (Th1, 
Th2, Th9, Th17, Th22, Treg,…) under the influence of  
cytokines, which on one hand can promote differentia-
tion into a specific subset or on the other hand block 
differentiation towards a functionally-opposing subset14. 
Th1 cells, producing pro-inflammatory cytokines (IL-2, 
IL-12, IFN-γ), support cell-mediated immunity and as 
a consequence promote inflammation, cytotoxicity, and 
delayed-type hypersensitivity; whereas Th2 cells, secreting 
anti-inflammatory cytokines (IL-4, IL-5, IL-13), support 
humoral immunity and down-regulate the inflammatory 
actions of  Th1 cells15-17. Other studies have shown the 
role of  adaptive immunity in insulin resistance observed 
in obesity-induced type 2 diabetes18-22. Indeed, obesity 
modulates the balance between the pro-inflammatory 
CD4+ T lymphocyte subpopulations (Th1 and Th17) 
and anti-inflammatory (Th2), and the increase of  CD8+ 
cytotoxic T cells and production of  pro-inflammatory cy-
tokines leading to the activation and infiltration of  mac-
rophages in adipose tissue18-23. It has been reported that 
CD4+CD25+ regulatory T cells can suppress inflamma-
tion of  adipose tissue and play a protective role against 
the insulin resistance induced by obesity24-26.  Of  note, 
regulatory T (Treg) cells were initially defined as a sub-
population of  suppressor T cells that mediate immune 
tolerance to self  and foreign antigens by suppressing au-
toreactive CD4+ or CD8+ T cells27,28. Several types of  
Treg cells have been identified and characterized as natu-
ral and adaptive/inducible Treg cells29. Natural Treg cells 
that originate in the thymus are self-reactive29, and pos-
sess ability to suppress the activation of  effector T cells in 
a cell-contact-dependent manner, cytokine-independent 
(interleukin-10,  (IL-10)-independent, and transforming 
growth factor,  (TGF-β)-independent manner27,28. How-
ever, the inducible Treg cells (iTreg) arise in the periphery, 
either during an immune response or after encountering 
tolerogenic dendritic cells30. They suppress  the  activa-
tion  of   effector  T cells  in  a cytokine-dependent  man-
ner: TGF-β for Th3 cells and IL-10 for T regulatory 1 
cells31.Understanding the relationship between T cell cy-
tokines and immune cell subtypes may reveal the clini-
cally relevant pathways that contribute to inflammation 
and insulinresistance observed in T2D. Thus, the present 
study was undertaken to investigate the profile of  Th1/
Th2 cytokines along with the frequencies of  leukocyte 
subpopulations of  innate and adaptive immune systems 
in insulin-treated type 2 diabetic patients.
Subjects and methods
Patients
Forty five insulin-treated type 2 diabetic patients between 
30 and 55 years of  age were selected from type 2 dia-
betic population at the Principal Insulin Bank (Diabetic 
Centre) of  Cotonou(Benin) where medical records were 
screened by specialist clinicians. Diabetes was diagnosed 
according to WHO criteria. They were non-obese or for-
mally obese people, with or without family records of  
diabetes, and in whom oral treatments, diet management 
and physical exercises were not favourable. They were all 
on insulin treatment. No patients received lipid lowering 
medications. None of  them had shown renal failure eval-
uated by renal impairment such as abnormal creatinemia, 
uraemia and macroalbuminuria. As controls, forty three 
healthy subjects were selected from the general healthy 
community in same study area. Control subjects and dia-
betic patients were matched with respect to age and body 
mass index (BMI) as determined by the weight and height 
of  patients. 
Control subjectss had no family history of  diabetes and 
showed normal fasting glycaemia measured twice at in-
clusion. As inclusion criteria, all participants were non-
smokers, had no significant history of  other illness, no 
pregnancy, no clinical signs of  infectious disease, no hep-
atitis B viral, no HIV and no malaria infection after blood 
sample tests. They lived in Cotonou (Littoral province, 
Benin) and within 5 km around the city, where the en-
demicity of  helminth infections has not been shown32,33. 
The anthropometric and clinical data of  diabetic and 
control subjects are shown in Table 1. Informed written 
consent was obtained from all individual participants in-
cluded in the study. The study was conducted in accor-
dance with the Declaration of  Helsinki (1964, as revised 
in Edinburgh 2000). The protocol was approved by the 
Ethics Committee on Research of  the Institute of  Ap-
plied Biomedical Sciences of  Cotonou, Benin under the 
number Dec.n°075/CER/ISBA-2015.
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Blood samples
From each patient or control subject, fasting venous 
blood samples were collected in tubes containing either 
EDTA or fluoride oxalate, or nothing to obtain respec-
tively plasma and serum by low-speed centrifugation 
(1000 g for 10 min). Plasma from fluoride oxalate tube 
was immediately used for blood glucose determinations. 
Serum was distributed in aliquots and frozen at – 80°C 
for future determinations of  insulin, lipids and T cell cy-
tokine concentrations. Whole blood samples of  EDTA 
tubes were used for immune cell subtype phenotyping. 
The quality of  serum and plasma was checked visually to 
ensure lack of  turbidity and hemolysis that may interfere 
with the assay results.
Determination of  plasma glucose and HbA1c and 
serum insulin and lipid concentrations
Plasma fasting glucose was determined by the glucose 
oxidase method using a glucose analyzer (Beckman In-
struments, Fullerton, CA). Glycosylated haemoglobin 
(HbA1c) levels were determined in the whole blood. 
HbA1c concentration was calculated using a percentage 
of  total haemoglobin, according to the manufacturer’s in-
structions (Ref. 41190, Labkit Chemelex SA, Barcelona, 
Spain). Serum triglycerides, total- and HDL-cholesterol 
concentrations were determined by using enzymatic 
methods, according to the instructions furnished with 
the kit (Boehringer, Mannheim, Germany). Serum insu-
lin concentrations were determined by using the Insulin 
IRMA kit (Ref. IM3210; Immunotech, Beckman Coulter 
Inc., Fullerton, CA) with a detection limit of  0.5 IU/ml. 
The interassay coefficients of  variability were 3.3 and 4%, 
respectively, for the concentrations 13 and 54 IU/ml.
 
Immune cell phenotyping
The frequencies of  innate immunity cells (monocytes, 
polynuclear eosinophils PNE, polynuclear neutrophils 
PNN, natural killer NK cells) and adaptive immunity cells 
(total lymphocytes, CD4+ T helper cells, CD8+ cytotox-
ic T cells, effector T cells and B cells) were determined 
in the whole blood by immunostaining with different 
specific monoclonal antibodies (mAbs) combinations. 
Briefly, whole blood was stained with appropriate com-
bination of  specific mAbs to allow identification of  T 
cell sub-populations. After incubation with the mAbs for 
30 min at 4°C in the dark, cells were washed and fixed 
with FACS lysing solution (BD Pharmigen). Anti-CD3-
FITC/ anti-CD4-PerCP/ anti-CD8-PE/ anti-CD25-PE/ 
anti-CD127-FITC/ anti-Foxp3-APC (BD Pharmigen) 
were used for T cell labeling, anti-CD19-FITC (BD Phar-
migen) for B lymphocytes, anti-CD16-PE/anti-CD56-
APC (BD Pharmigen) for NK cells, anti-CD14-FITC 
(BD Pharmigen) for monocytes and anti-CD16-PE (BD 
Pharmigen) for polynuclear cells. Anti-CD4-PerCP, anti-
CD25-PE and anti-CD127-FITC were used for Treg cell 
labeling. Anti-Foxp3-APC (BD Pharmigen) was added 
for intracellular staining of  Treg cells according to the 
manufacturer’s instructions, after permeabilisation and 
fixation with PermFix (BD Pharmigen). Of  notewor-
thy, we used a definition of  regulatory T cells (Treg, 
CD4+CD25+CD127-) for a sub-population of  CD4+ 
T cells that highly expressed Foxp3, thereby distinguish-
ing it from the sub-population defined as effector T cells 
(Teff, CD4+,CD25+,CD127+) (data not shown). The 
cells were finally resuspended in 300 µl of  staining buffer, 
acquired using FACSCalibur four-colour flow cytometer 
(BD Pharmigen, France) and analyzed using CellQuest 
Pro or FlowJo 7.6 software (BD Pharmigen, France). 
Gating strategies for immune cell phenotyping are shown 
in Figure 1a-g.
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Figure 1. Cytometry-based gating for definition of  phenotypes. (a) Monocytes (CD14+) were gated from mononuclear population in blood cells. (b) Eosinophils and neutrophils 
(CD16+) were gated from granulocyte population. (c) NK cells, non-T lymphocytes (CD16+CD56+) were gated from the total lymphocyte population. (d) B cells (CD19+) were 
gated from total lymphocytes. (e) CD4+ and (f) CD8+ T cells were gated from total lymphocyte population (CD3+). (g) Gating strategies for Treg (CD4+CD25+CD127-) and Teff  
(CD4+CD25+CD127+). Cell frequencies were determined as a percentage of  total lymphocytes (CD3+), and relative Foxp3 expression level determined as a function of  Foxp3 expres-
sion by CD4+ T cells
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Determination of  serum Th1/Th2 cytokine concen-
trations
Determination of  cytokine concentrations was per-
formed on serum samples that were stored at -80°C. Re-
peated freeze-thaw cycles were avoided. Cytokines were 
quantified by ELISA, using BioLegend human Th1/Th2 
ELISA MAXTM Deluxe set kits (BioLegend, San Diego, 
CA, USA), according to the manufacturer’s instructions.
Statistical analyses
Data analyses were performed using STATA/MP 11.2 
(StataCorp, College Station, TX, USA) and Graph Pad 
Prisme 5.0 (Graph Pad Inc, CA, USA). Values are means 
± SEM or medians ± IQR. The non-parametric Mann-
Whitney U test was employed for the comparison of  cell 
frequencies and cytokine levels between type 2 diabetic 
patients and control subjects. Anthropometric, clinical 
and biochemical data were compared between type 2 dia-
betic patients and control subjects, using Student’s t test. 
Differences were considered significant when p < 0.05.
Results
Blood glucose, serum insulin and lipid levels
Insulin-treated T2D patients were hyperglycemic and 
showed high level of  insulin as compared to healthy con-
trol subjects (Table 1).  Although insulin-treated T2D 
patients were normolipidemic, they showed significant 
low levels of  TG and total-cholesterol, as compared to 
control subjects; HDL-cholesterol did not differ between 
both groups (Table 1).
Table 1: Anthropometric and biochemical data of subjects 
  Control subjects 
(n = 43) 
Type 2 diabetic patients 
(n = 45) 
Male/female ratio 23/20 21/24 
Age 30-54 yr 30-55 yr 
BMI (kg/m2) 25.19 ± 1.90 26.38 ± 0.92 
Duration of disease (years) -                 9.9 ± 2.3 
       
BMI: Body Mass Index; HDL: High Density Lipoproteins; HbA1c: glycosylated hemoglobin. Values are means ± SEM. n = 43 
healthy control subjects; n = 45 type 2 diabetic patients. *p<0.05 and **p<0.01 indicate significant difference between type 2 
diabetic patients and healthy control subjects. Ranges of normal values: Fasting glucose: 3.88-6.10 mM (0.7-1.10 g/L); Total-
cholesterol: 3.23-6.46 mM (1.25-2.50 g/L) ; HDL-cholesterol: 1.16-1.94 mM (0.45-0.75 g/L); Triglycerides: 0.57-1.71 mM (0.50-
1.50 g/L); Urea: 2.50-7.49 mM (0.15-0.45 g/L) ; Creatinine: 53.04-123.76 µM (6-14 mg/L) ; HbA1c: 4-6 % ; Insulin: 1.21-14.5 
μUI/ml.  
Insulin treatment (% patients 






Fasting glucose (mM) 
  
5.05 ± 0.17 
  
9.55 ± 1.11** 
HbA1C (%) 4.25 ± 0.25 9.57 ± 1.56** 
Insulinemia (µUI/ml) 5.46 ± 0.77 10.93 ± 0.64** 
Urea (mM) 5.33 ± 0.33 5.49 ± 0.17 
Creatinemia (µM) 95.38 ± 6.31 98.30 ± 6.10 
Total cholesterol (mM) 5.64 ± 0.41 4.35 ± 0.36* 
HDL-cholesterol (mM) 1.63 ± 0.03 1.55 ± 0.05 
Triglycerides (mM) 1.23 ± 0.13 0.83 ± 0.11* 
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Immune cell frequencies are modified in type 2 dia-
betes
General analysis revealed that mononuclear cells declined 
while polynuclears did not change between insulin-treat-
ed T2D patients and healthy control subjects (Figure 2a-
b). The frequencies of  polynuclear neutrophils decreased 
while those of  monocytes, polynuclear eosinophils and 
natural killer cells did not change when comparing T2D 
patients to control subjects (Figure 2c-f).
Figure 2
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Figure 2. Frequencies (%) of  innate immunity cells in type 2 diabetic patients and control subjects. Cells were stained, as described in Ma-
terials and Methods section, in whole blood with appropriate combination of  specific monoclonal antibodies to allow identification of  cell 
sub-populations. (a) Total mononuclear cells; (b) Total polynuclear cells; (c) Natural killer cells ; (d) Monocytes ; (e) Polynuclear neutrophils ; 
(f) Polynuclear eosinophils. Cells were acquired using FACSCalibur four-colour flow cytometer (BD Pharmigen, France) and analyzed using 
CellQuest Pro or FlowJo 7.6 software (BD Pharmigen, France). Values are medians ± IQR. n = 43 healthy control subjects; n = 45 type 2 
diabetic patients. *p<0.05 or **p<0.01 indicate significant difference between type 2 diabetic patients and healthy control subjects.
The frequencies of  total lymphocytes declined in insulin-
treated T2D patients compared to control subjects, as 
shown in Figure 3a-b. Besides, CD8+ cytotoxic T cell fre-
quencies decreased (Figure 3d) in T2D patients whereas 
there was no change in the frequency of  CD4+ Th cells be-
tween both groups (Figure 3c). However, the frequencies 
of  effector CD4+ T cells (Teff, CD4+CD25+CD127+), 
regulatory T cells (Treg, CD4+CD25+CD127-) and B 
cells were significantly higher in insulin-treated T2D pa-
tients than in healthy control subjects (Figure 3e-f-g).
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in insulin-treated T2D patients compared with control 
subjects (Figure 4b). The Th1/Th2 ratios, determined as 
IL-2/IL-4, IL-2/IL-10, IFN-γ/IL-4, and IFN-γ/IL-10, 
demonstrated a shift towards IL-10-producing Teff  cell 
phenotype in type 2 diabetic patients (Table 2).
Type 2 diabetes modulates serum cytokine levels
Serum IL-2 and IFN-γ concentrations significantly di-
minished in insulin-treated T2D patients compared with 
control subjects (Figure 4a). Besides, IL-4 concentration 
























Figure 3. Frequencies (%) of adaptive immunity cells in type 2 diabetic patients and control subjects. Cells were 
stained, as described in Materials and Methods section, in whole blood with appropriate combination of specific 
monoclonal antibodies to allow identification of cells sub-populations. (a) Total lymphocytes; (b) CD3+ T cells; (c) 
Total CD4+ cells; (d) CD8+ T cells. (e) Effector CD4+T cells (CD4+CD25+CD127+); (f) Regulatory T cells (Treg, 
CD4+CD25+CD127-); (g) B lymphocytes. Cells were acquired using FACSCalibur four-colour flow cytometer (BD 
Pharmigen, France) and analyzed using CellQuest Pro or FlowJo 7.6 software (BD Pharmigen, France). Values are 
medians ± IQR. n = 43 healthy control subjects; n = 45 type 2 diabetic patients. *p<0.05 or **p<0.01 indicate 
significant difference between type 2 diabetic patients and healthy control subjects. 
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Table 2 : Ratios of serum Th1 and Th2 cytokine concentrations in subjects. 
  IL-2/IL-4 IL-2/IL-10 IFN-γ/IL-4 IFN-γ/IL-10 IL-4/IL-10 
Control subjects 2.16 1.49 5.91 4.07 0.69 
Type 2 diabetics 0.99§ 0.15§ 3.95§ 0.61§ 0.16§ 
 
Discussion
The pathological role of  the immune system in inflam-
mation and insulin resistance observed in type 2 dia-
betes mellitus has been suggested4-6. Indeed, cytokines 
produced by T cells interfere with insulin signalling and 
have been implicated in insulin resistance in type 2 dia-
betes mellitus34. In the present study, we investigated the 
profile of  T-cell derived Th1/Th2 cytokines along with 
percentages of  innate and adaptive immune system cells 
in insulin-treated type 2 diabetic patients. It’s well known 
that immune responses between male and female are not 
identical, since sexual hormones have been associated 
with prevalence, susceptibility, and severity of  autoim-
mune diseases35,36. However, we would like to mention 
that our results did not reveal any difference between 
male and female individuals, either in diabetic group or 
control group.
In the present study, we observed that as compared to 
control subjects, insulin-treated T2D patients were hyper-
glycemic, have showed high level of  insulin and high level 
of  HbA1c, reflecting a poor control of  diabetes37 and a 
decrease in insulin sensitivity in these patients, and this 
was in accordance with several reports38. Besides, we ob-
served that insulin-treated T2D patients were normolip-
idemic, even though they showed significant low levels of  
TG and total-cholesterol, as compared to control subjects; 
HDL-cholesterol did not differ between both groups. In 
fact, insulin treatment could account for lowering the lip-
ids (TG and total-chol) to normal levels in these patients, 
since insulin is known to enhance the activity of  lipo-







Figure 4. Serum Th1 (IL-2, INF-γ) and Th2 (IL-4, IL-10) cytokine concentrations in insulin-treated T2D patients 
and control subjects. Serum cytokine concentrations were determined as described in Materials and Methods. 
Values are medians ± IQR. n = 43 healthy control subjects; n = 45 type 2 diabetic patients. *p values indicate 
significant difference between type 2 diabetic patients and healthy control subjects. 
 
“Th1/Th2 and Th2/Th2 (last column) ratios were shifted toward Th2 phenotype in insulin-treated T2D patients. Values are ratios of  mean 
concentrations of  serum cytokines n = 43 healthy control subjects; n = 45 type 2 diabetic patients. The symbol (§) indicates significant dif-
ference between the two ratios”.
protein lipase, resulting in increase of  lipid metabolism 
and then decreased levels of  lipids39-41. Our results are 
in accordance with previous studies which have shown 
that insulin treatment could account for normalizing the 
levels of  total cholesterol, TG and LDL-cholesterol in 
type II diabetic patients under poor metabolic control40. 
Interestingly, the lipid-lowering action of  insulin, inde-
pendent of  glycemic control in T2D patients, appeared 
to be beneficial because of  the role of  dyslipidemia in the 
development of  diabetic macrovascular disease such as 
vasculopathy41.
In the present study, we observed that serum IL-2, INF-γ 
(Th1 cytokines) and IL-4 (Th2 cytokine) concentrations 
were down-regulated in insulin-treated T2D patients. In-
terestingly, the levels of  IL-10 were increased in these 
diabetic patients. Our observations suggested that di-
minished concentrations of  Th1 cytokines and increased 
IL-10 levels might contribute to the anti-inflammatory 
state observed in these patients. However, the diminished 
levels of  circulating IL-4 mightay be responsible for the 
induction of  diabetes mellitus. Our idea can be supported 
by the observations of  Muller et al.42 who showed that 
diabetes susceptibility was more associated with reduc-
tion of  IL-4 than with induction of  IFN-γ in islets of  
Balb/c diabetic mice. Similarly, Wood et al.16 have re-
ported diminished expression of  IL-4 in thymocytes of  
diabetic mice. Moreover, we have previously shown in 
clinical and experimental studies that a decrease of  IL-4 
may favour the onset of  diabetic pregnancy in humans9 
and animals10,11.
Type 2 diabetes has also been revealed as a chronic in-
flammatory disease promoted by changes in immune cell 
function and several studies have indicated that T cells 
are important mediators of  inflammation in this disease18, 
19,24,25. As far as innate immunity cells are concerned, we 
did not find significant differences in PNE, NK cells, 
and monocytes between insulin-treated T2D patients 
and controls, but we observed a tendency to a decrease 
in frequencies of  PNE and NK cells in type 2 diabetic 
patients. Additionally to this trend towards a decrease of  
PNE and NK cells, polynuclear neutrophils significantly 
decreased in insulin-treated T2D patients, suggesting a 
reduction of  innate immunity in these patients. However, 
it is important to mention that insulin-treated T2D pa-
tients exhibited a decline in their general immune defense 
system which was not only due to the decrease of  poly-
nuclear neutrophils, but also to the significant decrease of  
total mononuclear cells (as shown in the Fig 2a), mainly 
revealed by the significant reduction of  total lymphocytes 
(Fig 3a, 3b, 3d). Regarding adaptive immunity cells,we 
have mentioned above that insulin-treated T2D patients 
showed declined frequency of  total lymphocytes when 
compared to control subjects. Specifically, the decrease 
of  total lymphocytes was revealed by the diminished per-
centages of  circulating CD3+ T and CD8+ cytotoxic T 
cells and no change in the frequency of  CD4+ T cells 
between both groups. Similar results have been reported 
by Nishimura et al.18 who have observed a lower CD8+ T 
cell counts in peripheral blood from ob/ob mice. One hy-
pothesis to explain the low number of  circulating CD8+ 
T cell in T2D patients, in ourthis study, could be a prefer-
ential relocation of  these cells in adipose tissue18. Indeed, 
it has been reported a decreased number of  peripheral 
CD8+ T cells and an increased infiltration of  these cells 
in adipose tissue of  ob/ob mice which contribute tomac-
rophage recruitment and adipose tissue inflammation in 
obesity and insulin resistance18,24. Thus, the concomitant 
reduction of  innate immunity and decline of  total CD3+ 
lymphocytes and CD8+ T cells in insulin-treated T2D 
patients might suggest a decreased level of  generalim-
mune defense system (see below)15,16.
Recent data have supported the protective role of  Treg 
cells against inflammation inadipose tissue and insulin re-
sistance observed during obesity and type 2 diabetes24,26. 
In the present study, the concomitant increase of  Treg cell 
frequency with the decline of  total lymphocytes in insulin-
treated T2D patients reinforces our hypothesis of  a low 
immune defense system in these patients15,16. Our results 
did not support those obtained by Zeng et al. 43who have 
observed that peripheral induced CD4+Foxp3+Helios(-) 
Treg cells were decreased in T2D patients. Jagannathan-
Bogdan et al.19 have also observed that T2D patients had 
decreased percentages of  CD4+ Treg cells. Be that as it 
may, our study shown increased frequencies of  Treg cells 
in T2D patients and, this is consistent with anti-inflam-
matory profile of  these patients and might be partially 
explained by their insulin treatment. Indeed, it has been 
well established that insulin exerts anti-inflammatory ac-
tivity through the inhibition of  the production of  pro-
inflammatory cytokines by macrophages44-46. It is thus 
interesting to observe that insulin-treated T2D patients 
have shown decreased levels of  pro-inflammatory Th1 
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cytokines (IL-2/IFN-γ). Similarly, Dimitriadis et al.47 
have shown in human studies that high insulin resulted in 
thereduction of  infiltration and accumulation of  macro-
phages in the tissues. Other investigators45,46 have shown 
that insulin exerts anti-inflammatory activity by inhibit-
ing the secretion pro-inflammatory cytokines IL-1β, IL-8 
and TNF-α. Based on studies cited above44,45,47, we can 
state that insulin treatment in T2D patients, in the pres-
ent study, might contribute to low numberof  total lym-
phocytes (CD3+ and CD8+ T cells) and high frequency 
of  Treg cells which might be related to low cell-mediated 
adaptive immunity in these patients, since Treg cells are 
known to suppress the activation of  CD4+ and CD8+ T 
cells15,16,27,28. 
 
In the present study, insulin-treated T2D patients exhibit-
ed an increased frequency of  B lymphocytes and showed 
anti-inflammatory profile revealed by high level of  circu-
lating IL-10. However, other investigators have reported 
that B cells induce insulin resistance, regulate inflamma-
tion and promote pro-inflammatory T cell functions and 
cytokines in type 2 diabetes 20, 48, which appeared to 
becontradictory to that we described in this study.  To ad-
dress this dichotomy, we have calculated ratios of  B-cell: 
Teff  and B-cell:Treg. We found that the ratio value of  T2D 
patients (B-cell:Teff=5.27) was 1.41-fold of  that of  con-
trol subjects (B-cell:Teff=3.73), and (B-cell:Treg=1.42) 
of  T2D patients was 3.0-fold of  that of  control subjects 
(B-cell:Treg=0.47), suggesting that the predominance 
was in favor of  B-cells in T2D patients. Nevertheless, the 
general idea that we described in this study is that T2D 
patients showed anti-inflammatory profileand increased 
B lymphocytes due to insulin treatment, consistent with 
Th2 phenotype. Be that it may, our results revealed that a 
cross-talk would exist between insulin level and the num-
ber of  B lymphocytes in type 2 diabetes mellitus and, this 
need to be explored.
Furthermore, insulin-treated T2D patients exhibited 
high frequency of  differentiated Teff  cells, defined as 
CD4+Th subpopulation that express CD25+CD127+ 
and less Foxp-3 protein. Concomitantly, the level of  cir-
culating IL-10 (Th2 cytokines) was significantly increased 
while those of  IFN-γ and IL-2 were decreased in T2D 
patients, suggesting that CD4+ Th0 cells in T2D patients 
have preferentially differentiated into (IL-10-producing) 
Th2 effector cells. It is recognized that IL-10 is produced 
by several types of  cells including Treg cells, CD4+Teffh2 
cell, Breg cells….10-13,31,49. However, we would like to spec-
ify that Treg cells represent 1–3% of  total CD4+ T-cells 
in human27-29. Although Treg cells increased in T2D pa-
tients, increase of  IL-10 would not be attributed only to 
Treg cell production since CD4 Th2 cells also increased 
in these patients. 
To decide between these two opinions, we calculated the 
Teff:Treg ratios. We found that the ratio value of  T2D 
patients (Teff:Treg=0.27) is 2.1-fold of  that of  control 
subjects (Teff:Treg=0.12), suggesting that the observed 
increase of  IL-10 in T2D patients was in favor of  Teff  
cells. On the one hand, Under these observationcondi-
tions described above suggested,  we can assume that 
IL10 comes, in large part, from Teff, cells confirming 
the preferential differentiation of  CD+Th cells into (IL-
10-producing) Th2 effector cells in insulin-treated T2D 
patients. Our idea was supported by Th1/Th2 ratios cal-
culated as IL-2/IL-4, IL-2/IL-10, IFN-γ/IL-4, IFN-γ/
IL-10 which demonstrated a down-regulation of  Th1 and 
up-regulation of  Th2 profile in T2D patients. In fact, the 
Th2 profile exhibited by insulin-treated T2D patients is 
consistent with the anti-inflammatory profile of  these pa-
tients43-45. 
To highlight the comparatively enhanced anti-inflamma-
tory profile in T2D patients, we have calculated Th2/Th2 
ratio representing IL4/IL10 which declined from control 
subjects (0.69) to diabetic patients (0.16). These observa-
tions suggest that the absolute amount of  Th2 cytokines 
(IL-4 and IL-10) was in favor of  IL-10 in patients with di-
abetes, confirming the anti-inflammatory profile of  these 
patients. Nonetheless, it would be interesting to keep in 
mind the emerging evidence on the dynamic functional 
plasticity of  Treg cells into either pro-inflammatory or 
anti-inflammatory effector cells50. Thus, it would be logi-
cally useful to admit another plausible explanation of  the 
present results. The augmented levels of  IL-10 in insulin-
treated T2D patients might be, on the other hand, the 
results of  cumulative secretion of  Treg cells, B cells and 
Teff  cells, since this cytokine increased concomitantly 
with the enhanced frequencies of  these cells observed 
in T2D patients. Indeed, it has been reported that IL-
10 is produced by several types of  cells including Treg 
cells, CD4+Teff  cell, Breg cells10-13,31,49.  Although the de-
scribed dynamic functional plasticity of  Treg cells 50, the 
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concomitant increase of  Teff  cells along with Treg cells 
maysuggest an anti-inflammatory status in insulin-treated 
diabetic patients, since Treg cells are known to possess 
anti-inflammatory properties24-26.
Taken together, our study showed that insulin-treated 
type 2 diabetes mellitus appears to be associated with a 
down-regulation of  immune defense system consistent 
with increased number of  Treg cells and CD4+ Th cell 
differentiation towards IL-10-producing Teff-cells anti-
inflammatory Th2 phenotype associated with B cell ex-
pansion. To sum-up, our results provide evidence that 
insulin therapy in T2D patients contributes to normalis-
ing dyslipidemia and may confer to these patients anti-
inflammatory profile with high production of  IL-10 and 
this may probably diminish their susceptibility to certain 
infections or autoimmune and inflammatory diseases. 
Further studies are required to explore insulin action in 
the modulation of  inflammatory parameters such as adi-
pocytokines (IL-6, TNF-α, adiponectin, leptin...), through 
T cell derived-cytokines and differentiation in type 2 dia-
betes mellitus.
Conflict-of-interest disclosure statement
All of  the authors have nothing to declare as far as the 
conflict of  interest is concerned. The authors also declare 
no competing commercial interests.
References
1. American Diabetes Association (ADA). Diagnosis and 
classification of  Diabetes Mellitus. Diabetes Care 2008; 31: 
55-60.
2. Chaker L, Falla A, van der Lee SJ, Muka T, Imo D, 
Jaspers L, et al. The global impact of  non-communicable 
diseases on macro-economic productivity: a systematic 
review. Eur J Epidemiol 2015;30:357-95.
3. World Health Organization. Definition, diagnosis and 
classification of  diabetes mellitus and its complications. 
Part 1: Diagnosis and classification of  diabetes melli-
tus. Geneva, World Health Organization Report, 1999 
(WHO/NCD/NCS/99.2), p 65.
4. Sathyapalan T, Atkin SL. Is there a role for immune 
and anti-inflammatory therapy in type 2 diabetes? Minerva 
Endocrinol 2011; 36: 147-156.
5. Li ZZ, Liu JB, Li L, Jiao L, Chen L. Intensive therapy 
for diabetes throughinfluence on innate immune system. 
Med Hypotheses 2009; 72: 675-676 PubMed .
6.  Ehses JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud 
J, Kassis N, et al. IL-1 antagonism reduces hyperglycemia 
and tissue inflammation in the type 2 diabetic GK rat. 
Proc Natl Acad Sci U S A 2009;106:13998-14003
7. Pickup JC, Crook MA. Is type II diabetes mellitus a 
disease of  the innate immune system? Diabetologia 1998; 
41: 1241-1248.
8. Pickup JC, Mattock MB, Chusney GD, Burt D. NI-
DDM as a disease of  the innate immune system: asso-
ciation of  acute phase reactants and interleukin-6 with 
metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
9. Ategbo JM, Grissa O, Yessoufou A, Hichami A, Dra-
mane KL, Moutairou K, et al.Modulation of  adipokines 
and cytokines in gestational diabetes and macrosomia. J 
Clin Endocrinol Metab 2006; 91:4137-43.
10. Khan NA, Yessoufou A, Kim M, Hichami A. N-3 
fatty acids modulate Th1 and Th2 dichotomy in diabetic 
pregnancy and macrosomia. J Autoimmun 2006; 26:268–
277.
11. Yessoufou A, Hichami A, Besnard P, Moutairou, 
Khan NA. PPARα deficiency increases the risk of  mater-
nal abortion and neonatal mortality in murine pregnancy 
with or without diabetes mellitus: modulation of  T cell 
differentiation. Endocrinology 2006; 147:4410-4418.
12. Yessoufou A, Moutairou K. Maternal diabetes in preg-
nancy: early and long-term outcomes on the offspring 
and the concept of  "metabolic memory".  Exp Diabetes 
Res. 2011;2011:218598. doi: 10.1155/2011/218598.
13. Yessoufou A, Plé A, Moutairou K, Hichami A, Khan 
NA. Docosahexaenoic acid reduces suppressive and mi-
gratory functions of  CD4+CD25+ regulatory T-cells. J 
Lipid Res 2009; 50:2377-88 PubMed .
14. Baranovski BM, Freixo-Lima GS, Lewis EC, Rider P. T 
Helper Subsets, Peripheral Plasticity, and the Acute Phase 
Protein, α1-Antitrypsin. Biomed Res Int. 2015;2015:184574. 
doi: 10.1155/2015/184574.
15. Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional 
regulation of  Th1/Th2 polarization. Immunol Today  2000; 
21: 479-483.
16. Wood SC, Rao TD, Frey AB.  Multidose streptozoto-
cin induction of  diabetes in BALB/cBy mice induces a T 
cell proliferation defect in thymocytes which is reversible 
by interleukin-4. Cell Immunol 1999; 192: 1-12.
17. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 
CD4 þ T cells in the pathogenesis of  organ-specific auto-
immune diseases. Immunol Today 1995; 16:34e8.
African Health Sciences Vol 16 Issue 3, September 2016 722
18. Nishimura S, Manabe I, Nagasaki M, Eto K, Ya-
mashita H, Ohsugi M. CD8+ effector T cells contribute 
to macrophage recruitment and adipose tissue inflamma-
tion in obesity. Nat Med 2009; 15: 914-920.
19. Jagannathan-Bogdan M, McDonnell ME, Shin H, 
Rehman Q, Hasturk H, Apovian CM. Elevated proin-
flammatory cytokine production by a skewed T cell com-
partment requires monocytes and promotes inflamma-
tion in type 2 diabetes. J Immunol 2011; 186: 1162-1172.
20. Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Palt-
ser G, et al. B Lymphocytes Promote Insulin Resistance 
through Modulation of  T Lymphocytes and Production 
of  Pathogenic IgG Antibody. Nat Med 2011; 17: 610-617.
21. Chawla A, Nguyen KD, Goh YP. Macrophage-medi-
ated inflammation in metabolic disease. Nat Rev Immunol 
2011; 11: 738-749.
22. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a 
phenotypic switch in adipose tissue macrophage polariza-
tion. J Clin Invest 2007; 117: 175-184.
23. Wentworth JM, Naselli G, Brown WA, Doyle L, Phi-
pson B, Smyth GK. Pro-inflammatory CD11c+CD206+ 
adipose tissue macrophages are associated with insulin 
resistance in human obesity. Diabetes 2010; 59: 1648-1656.
24. Deiuliis J, Shah Z, Shah N, Needleman B, Mikami D, 
Narula V. Visceral adipose inflammation in obesity is as-
sociated with critical alterations in T regulatory cell num-
bers. PLoS One 2011 Jan 26; 6(1): e16376. doi: 10.1371/
journal. pone.0016376.
25. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bah-
rami J. Normalization of  obesity-associated insulin resis-
tance through immunotherapy. Nat Med 2009; 15: 921-
929.
26. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, 
Nayer A. Lean, but not obese, fat is enriched for a unique 
population of  regulatory T cells that affect metabolic pa-
rameters. Nat Med 2009; 15: 930-939.
27. Sakaguchi S.  Regulatory T cells:  key controllers of  
immunologic self-tolerance. Cell 2000; 101: 455-458.
28. Shevach EM. CD4+ CD25+ suppressor T cells: more 
questions than answers. Nat Rev Immunol 2002; 2: 389-400.
29. Bluestone JA, Abbas AK. Natural versus adaptive reg-
ulatory T cells. Nat Rev Immunol 2003;3: 253-257. Review.
30. Groux H. An overview of  regulatory T cells. Microbes 
Infect 2001; 3: 883-9.
31. Buckner JH, Ziegler SF. Regulating the immune sys-
tem: the induction of  regulatory T cells in the periphery. 
Arthritis Res Ther 2004; 6: 215-22 Review.
32. Ibikounlé M, Satoguina J, Fachinan R, Tokplonou L, 
Batcho W, Kindé-Gazard D, Mouahid G, Moné H, Mas-
sougbodji A, Courtin D. Epidemiology of  urogenital 
schistosomiasis and soil-transmitted helminths among 
schoolchildren of  Lake Nokoue areas of  Sô-Ava, south 
Benin. J. Appl. Biosci 2013; 70:5632– 5639.
33.  Ibikounlé M, Ogouyèmi-Hounto A, de Tové YS, 
Dansou A, Courtin D, Kindé-Gazard D, Mouahid G, 
Moné H, Massougbodji A. Epidemiology of  urinary 
schistosomiasis among school children in Péhunco area, 
Northern Benin. Malacological survey. Bull Soc Pathol Exot 
2014; 107(3):177-84.
34. Greenberg AS, McDaniel ML. Identifying the links 
between obesity, insulin resistance and ß-cell function: 
potential role of  adipose- derived cytokines in the patho-
genesis of  type 2 diabetes. Eur J Clin Invest 2002;32: 24-34.
35. Buggage RR, Matteson DM, Shen de F, Sun B, Tuail-
lon N, Chan CC 2003 Effect of  sex hormones on experi-
mental autoimmune uveoretinitis (EAU). Immunol Invest 
32:259-273.
36.  Klein SL, Bird BH, Glass GE 2001 Sex differences in 
immune responses and viral shedding following Seoul vi-
rus infection in Norway rats. Am J Trop Med Hyg 65:57-63. 
37.  Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg 
R. Metabolic syndrome: a comprehensive perspective 
based on interactions between obesity, diabetes and in-
flammation. Circulation 2005; 111:1448-1454.
38. Catalano PM, Kirwan JP, Haugel- de Mouzon S, 
King J. Gestational diabetes and insulin resistance: role in 
short- and long-term implications for mother and fetus. J 
Nutr 2003; 133: 1674-1683.
39.  Farese RV, Yost TJ, Eckel RH. Tissue-specific regula-
tion of  lipoprotein lipase activity by insulin/glucose in 
normal-weight humans. Metabolism 1991; 40: 214-216.
40. Scoppola A, Testa G, Frontoni S, Maddaloni E, Gam-
bardella S, Menzinger G, et al. Effects of  insulin on cho-
lesterol synthesis in type II diabetes patients. Diabetes Care 
1995; 18: 1362-1369.
41. Feitosa AC, Feitosa-Filho GS, Freitas FR, Wajchenberg 
BL, Maranhão RC. Lipoprotein metabolism in patients 
with type 1 diabetes under intensive insulin treatment. 
Lipids Health Dis 2013; Feb 11;12:15. doi: 10.1186/1476-
511X-12-15.
42.  Muller S, Martin S, Koenig W, Hanifi-Moghaddam P, 
Rathmann W, Haastert B, et al. Impaired glucose toler-
ance is associated with increased serum concentrations 
of  interleukin 6 and co-regulated acute-phase proteins 
African Health Sciences Vol 16 Issue 3, September 2016723
but not TNF-alpha or its receptors. Diabetologia 2002; 45: 
805-812.
43. Zeng C, Shi X, Zhang B, Liu H, Zhang L, Ding W, et 
al. The imbalance of  Th17/Th1/Tregs in patients with 
type 2 diabetes: relationship with metabolic factors and 
complications. J Mol Med (Berl) 2012; 90(2):175 PubMed 
-86.
44. Xiu F, Stanojcic M, Diao L, Jeschke MG. Stress Hyper-
glycemia, Insulin Treatment, and InnateImmune Cells. Int J 
Endocrinol 2014;2014:486403. doi: 10.1155/2014/486403.
45. Sarigianni M, Bekiari E, Tsapas A. Effect of  glucose 
and insulin on oxidized low density lipoprotein phagocy-
tosis by human monocytes: a pilot study. Angiology 2011; 
62: 163-166.
46. Wurm S, Neumeier M, Weigert J. Insulin induces 
monocytic CXCL8 secretion by the mitogenic signalling 
pathway. Cytokine 2008; 44: 185-190.
47. Dimitriadis G, Maratou E, Boutati E, Psarra K, Pap-
asteriades C, Raptis SA. Evaluation of  glucose transport 
and its regulation by insulin in human monocytes using 
flow cytometry. Cytometry Part A 2005; 64: 27-33.
48. DeFuria J, Belkina AC, Jagannathan-Bogdan M, Sny-
der-Cappione J, Carr JD, Nersesova YR, et al. B cells pro-
mote inflammation in obesity and type 2 diabetes through 
regulation of  T-cell function and an inflammatory cyto-
kine profile. Proc Natl Acad Sci U S A. 2013; 110:5133-
5138.
49. Sun J, Wang J, Pefanis E, Chao J, Rothschild G, 
Tachibana I, et al. Transcriptomics Identify CD9 as a 
Marker of  Murine IL-10-Competent Regulatory B Cells. 
Cell Rep 2015; 13(6):1110-1117.
50.  Campbell DJ, Koch MA. Phenotypical and functional 
specialization of  FOXP3+ regulatory T cells. Nat Rev Im-
munol. 2011;11(2):119-30. doi: 10.1038/nri2916.
African Health Sciences Vol 16 Issue 3, September 2016 724
